WEKO3
アイテム
Tegafur plus Medroxyprogesterone acetate for Adriamycin- and Tamoxifen-resistant advanced breast cancers
https://kindai.repo.nii.ac.jp/records/2003122
https://kindai.repo.nii.ac.jp/records/20031222f587baf-7ba0-4cb2-9d76-1c808ef08730
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
AA0050842X-19950600-0069.pdf (540.2 KB)
|
|
| Item type | 紀要論文 / departmental bulletin paper(1) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 公開日 | 2025-07-08 | |||||||||||||||||||
| タイトル | ||||||||||||||||||||
| タイトル | Tegafur plus Medroxyprogesterone acetate for Adriamycin- and Tamoxifen-resistant advanced breast cancers | |||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 作成者 |
Wada, Tomio
× Wada, Tomio
× Nishiyama, Kouichiro
× Houjou, Toshiya
× Yamauchi, Eiju
× Nakatani, Yoshihiro
× Inui, Hiroki
× Yasutomi, Masayuki
|
|||||||||||||||||||
| 言語 | ||||||||||||||||||||
| 言語 | eng | |||||||||||||||||||
| キーワード | ||||||||||||||||||||
| 主題 | Breast Cancer, chemoendocrine therapy, drug-resistance, medroxyprogesterone acetate, tamoxifen | |||||||||||||||||||
| 内容記述 | ||||||||||||||||||||
| 内容記述タイプ | Abstract | |||||||||||||||||||
| 内容記述 | A total of 32 patients with advanced breast cancer whose tumors were resistant to both adriamycin (ADR) and tamoxifen (TAM) were treated with combined chemoendocrine treatment with tegafur and medroxyprogesterone acetate (MPA). The daily dose of tegafur and MPA was 800 mg/body. Two patients were assessed as complete response (CR), 8 as partial response (PR), 12 as no change (NC) and 10 as progressive disease (PD). The overall response rate was 31% (95% CI : 16.1-50.0%). A better response was observed in estrogen receptor (ER) positive and unknown patients than in ER negative patients, and in the patients with long disease-free intervals than in those with short intervals. The 50% survival period by the Kaplan Meier method was 88 weeks and the median duration of response was 14 weeks. Good quality of life was maintained during treatment because of lowered side effects. Tegafur plus MPA therapy is useful for the treatment of advanced breast cancers which are resistant to ADR and TAM. | |||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 出版者 | ||||||||||||||||||||
| 出版者 | The Kinki University Medical Association | |||||||||||||||||||
| 言語 | en | |||||||||||||||||||
| 資源タイプ | ||||||||||||||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||||||||||||||||
| 資源タイプ | departmental bulletin paper | |||||||||||||||||||
| 出版タイプ | ||||||||||||||||||||
| 出版タイプ | AM | |||||||||||||||||||
| 出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||||||||||||||||
| 収録物識別子 | ||||||||||||||||||||
| 収録物識別子タイプ | PISSN | |||||||||||||||||||
| 収録物識別子 | 03866092 | |||||||||||||||||||
| 開始ページ | ||||||||||||||||||||
| 開始ページ | 69 | |||||||||||||||||||
| 終了ページ | ||||||||||||||||||||
| 終了ページ | 75 | |||||||||||||||||||
| 書誌情報 |
en : ACTA MEDICA KINKI UNIVERSITY 巻 20, 号 2, p. 69-75, 発行日 1995-06 |
|||||||||||||||||||
